PRVL Prevail Therapeutics Inc.

10.16
+0.27  (+3%)
Previous Close 9.89
Open 9.83
Price To Book 1.72
Market Cap 345,655,331
Shares 34,021,194
Volume 67,194
Short Ratio
Av. Daily Volume 77,529
Stock charts supplied by TradingView

NewsSee all news

  1. Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases

    Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases Companies to partner on process

  2. Prevail Therapeutics to Present at Upcoming October Conferences

    NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or "the Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  3. Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes

    NEW YORK, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or "the Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  4. Prevail Therapeutics Provides Program Update on PR001 in Parkinson's Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders, today provided an update

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated 1H 2020.
PR001
Neuronopathic Gaucher disease
Phase 1/2 trial to be initiated 2H 2019.
PR001
Parkinson’s disease with GBA1 mutation

Latest News

  1. Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases

    Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases Companies to partner on process

  2. Prevail Therapeutics to Present at Upcoming October Conferences

    NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or "the Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  3. Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes

    NEW YORK, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or "the Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  4. Prevail Therapeutics Provides Program Update on PR001 in Parkinson's Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders, today provided an update